Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same
First Claim
1. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
- (a) contacting a proinsulin polypeptide with an oligomer comprising a hydrophilic moiety and/or a lipophilic moiety under conditions sufficient to couple the oligomer to the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, wherein the proinsulin polypeptide comprises;
(i) an insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide; and
(ii) one or more non-insulin polypeptides coupled to the insulin polypeptide by peptide bond(s) capable of being cleaved to yield the insulin polypeptide; and
(b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.
3 Assignments
0 Petitions
Accused Products
Abstract
Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.
-
Citations
137 Claims
-
1. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
-
(a) contacting a proinsulin polypeptide with an oligomer comprising a hydrophilic moiety and/or a lipophilic moiety under conditions sufficient to couple the oligomer to the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, wherein the proinsulin polypeptide comprises; (i) an insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide; and (ii) one or more non-insulin polypeptides coupled to the insulin polypeptide by peptide bond(s) capable of being cleaved to yield the insulin polypeptide; and (b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)
-
-
81. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
-
(a) contacting a proinsulin polypeptide comprising an insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide, the insulin polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide, with an oligomer comprising the structure of Formula I;
A-Lj-Gk-R-G′
m-R′
-G″
n-T
(I)wherein; A is an activatable moiety; L is an optional linker moiety; G, G′ and
G″
are each optional spacer moieties;R is a lipophilic moiety and R′
is a polyalkylene glycol moiety, or R′
is the lipophilic moiety and R is the polyalkylene glycol moiety, and wherein, (i) R and R′
are both present, or (ii) R and G are absent and L is coupled to G′
if present or to R′
if G′
is not present, or (iii) R′ and
G″
are absent and T is coupled to G′
if present or to R if G′
is not present;T is a terminating moiety; and j, k, m and n are individually 0 or 1; under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and (b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. - View Dependent Claims (82, 83, 84, 85, 86, 87, 88, 89, 90, 91)
-
-
92. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
-
(a) contacting a proinsulin polypeptide comprising an insulin polypeptide, the insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide and coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide, with an activated form of an oligomer comprising the structure of Formula II;
A-X(CH2)mY(C2H4O)nR
(II)wherein; A is —
C(O)—
OH, C(S)—
OH, —
C(S)—
SH, —
OH, —
SH, or NH2;X is an oxygen atom or a covalent bond, with the proviso that X is not an oxygen atom when A is —
OH;Y is an ester, an ether, a carbamate, a carbonate, or an amide bonding moiety; m is between 0 and 30; n is between 0 and 50; m and n are not both 0; and R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety; under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and (b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. - View Dependent Claims (93, 94, 95, 96, 97, 98, 99, 100, 101)
-
-
102. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
-
(a) contacting a proinsulin polypeptide comprising an insulin polypeptide, the insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide and coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide, with an activated form of an oligomer comprising the structure of Formula III;
A-(CH2)m(OC2H4)nOR
(III)wherein; A is —
C(O)—
OH, C(S)—
OH, —
C(S)—
SH, —
OH, —
SH, or NH2;m is between 0 and 25; n is between 0 and 25; m and n are not both 0; and R is alkyl; under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and (b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. - View Dependent Claims (103, 104, 105, 106, 107, 108, 109, 110, 111)
-
-
112. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:
(a) contacting a proinsulin polypeptide comprising;
(i) an insulin polypeptide, the insulin polypeptide having a human A-chain polypeptide and a human B-chain polypeptide, which human B-chain polypeptide comprises a lysine residue;
(ii) a connecting peptide coupled at a first end to the C-terminus of the human B-chain polypeptide and coupled at a second end to the N-terminus of the human A-chain polypeptide; and
(iii) a leader peptide coupled to the N-terminus of the human B-chain polypeptide with an activated form of an oligomer comprising the structure of Formula IV;- View Dependent Claims (113, 114, 115, 116, 117, 118, 119, 120, 121)
-
122. A method of synthesizing an insulin-oligomer conjugate comprising:
(a) contacting a proinsulin polypeptide, which comprises an insulin polypeptide, the insulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide and coupled at its N-terminus to a leader peptide, with an activated form of an oligomer comprising the structure of Formula V; - View Dependent Claims (123, 124, 125)
-
126. A method of synthesizing a human insulin polypeptide-acyl oligomer conjugate comprising enzymatically cleaving one or more non-insulin polypeptides from a proinsulin polypeptide-acyl oligomer conjugate to provide the human insulin polypeptide-acyl oligomer conjugate.
- 127. A method of synthesizing an insulin-acyl oligomer conjugate comprising enzymatically cleaving a leader peptide and a C-peptide from a proinsulin polypeptide-acyl oligomer conjugate comprising the following structure:
-
134. A method of synthesizing a proinsulin polypeptide-oligomer conjugate, the proinsulin polypeptide comprising a human A-chain polypeptide and a human B-chain polypeptide, the method comprising contacting a proinsulin polypeptide with an oligomer comprising a hydrophilic moiety and a lipophilic moiety under conditions sufficient to provide the proinsulin polypeptide-oligomer conjugate.
-
135. A method of synthesizing a C-peptide polypeptide-oligomer conjugate comprising:
-
(a) contacting a pro-C-peptide polypeptide comprising a human C-peptide polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) that are cleavable to yield the human C-peptide polypeptide with an oligomer under conditions sufficient to couple the oligomer to the human C-peptide polypeptide portion of the pro-C-peptide polypeptide and provide a pro-C-peptide polypeptide-oligomer conjugate; and (b) cleaving the one or more non-insulin polypeptides from the pro-C-peptide polypeptide-oligomer conjugate to provide the human C-peptide polypeptide-oligomer conjugate. - View Dependent Claims (136, 137)
-
Specification